Similar articles

• Terje Rolf Pedersen, MD: a conversation with the editor. Interview by William Clifford Roberts.

  Pedersen TR. Pedersen TR. Am J Cardiol. 1999 Nov 15;84(10):1234-45. doi: 10.1016/s0002-9149(99)00552-4. Am J Cardiol. 1999. PMID: 10569335 No abstract available.
• Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.

  Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Shepherd J, et al. Atheroscler Suppl. 2004 Oct;5(3):115-23. doi: 10.1016/j.atherosclerosissup.2004.08.032. Atheroscler Suppl. 2004. PMID: 15531284 No abstract available.
• Cardiovascular primary prevention: how high should we set the bar?

  Prasad V, Vandross A. Prasad V, et al. Arch Intern Med. 2012 Apr 23;172(8):656-9; discussion 659. doi: 10.1001/archinternmed.2012.812. Arch Intern Med. 2012. PMID: 22529231
• Implications of the heart protection study for reducing coronary events in high-risk patients.

  Brown WV, Davis W, Harris M. Brown WV, et al. Curr Atheroscler Rep. 2003 Sep;5(5):358-63. doi: 10.1007/s11883-003-0006-1. Curr Atheroscler Rep. 2003. PMID: 12911845 Review. No abstract available.
• [The factors that condition the efficacy of and indications for statins in cardiovascular prevention].

  Pintó Sala X. Pintó Sala X. Aten Primaria. 1999 Mar 15;23(4):227-30, 232-4. Aten Primaria. 1999. PMID: 10333608 Review. Spanish. No abstract available.